Highlights
A collection of news and information related to AstraZeneca Plc published by this site and its partners.
Displaying items 1-12 of 71
» View wsbtradio.com items only
1
2
3
4
5
6
•
Next >
-
Dollar firms as Fed suspense builds, shares off highs
ReutersLONDON (Reuters) - The dollar edged up, gold steadied and European shares held near five-year highs on Tuesday as investors look out for U.S. Federal Reserve signals on the future of its stimulus program. Upbeat comments from Chicago policymaker...Tags: Alcoa Incorporated, Good Friday, Interior Policy, United Nations, Wells Fargo & Co.
-
AstraZeneca closes in on site for new home in Cambridge
Reuters* Drugmaker eyes Cambridge Biomedical Campus - sources * Relocation centrepiece of new CEO's restructuring plan * New research centre and corporate HQ to cost some $500 mln By Ben Hirschler and Tom Bill LONDON, May 20 (Reuters) - AstraZeneca is...Tags: Science and Technology, Elizabeth II, Entertainment Events, Biology, Research
-
Mexicana Genomma Lab distribuirá marca de antiácidos Losec
ReutersMONTERREY, 20 mayo (Reuters) - La farmacéutica mexicana Genomma Lab dijo el lunes que firmó un contrato de licencia para el uso de la marca de medicamentos de libre venta Losec, que le permitirá distribuir el popular antiácido por 99 años. Genomma... -
AstraZeneca accelerates cancer drug testing
ReutersLONDON (Reuters) - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group's new CEO delivers on a promise to accelerate its oncology programs. Britain's second-biggest drugmaker...Tags: Science and Technology, Trials, Lung Cancer, Drugs and Medicines, Medical Specialization
-
Cubist bid almost $1 bln for Optimer before sale process-sources
ReutersBy Jessica Toonkel NEW YORK, May 15 (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people...Tags: Cubist Pharmaceuticals Incorporated, Diarrhea, Japan, Thomson Corporation
-
Cubist bid for Optimer before sale process began: sources
ReutersNEW YORK (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters...Tags: Cubist Pharmaceuticals Incorporated, Diarrhea, Japan, Thomson Corporation
-
A taste for defensives sours prospects for European stocks
Reuters* Defensive stocks unusually leading Europe stock rally * Healthcare price/earnings ratios at five-year highs * Fund managers still favour defensives -BofA ML survey By Tricia Wright LONDON, May 14 (Reuters) - Defensive stocks such as healthcare...Tags: Earnings, Companies and Corporations, Mutual Funds, Thomson Corporation, Finance
-
RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Repeats to widen readership) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc...Tags: Science and Technology, Arthritis, Consumers, Drugs and Medicines, Social Sciences
-
U.S. spending on medicines fell for first time in 2012
Reuters(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. Overall U.S....Tags: Flu, Patents, Copyrights and Trademarks, Health Insurance Cost, Pfizer Inc., Lipitor (drug)
-
XxANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
ReutersBy Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown...Tags: Science and Technology, Arthritis, Consumers, Drugs and Medicines, Social Sciences
-
REFILE-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Removes "XX" from headline) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and...Tags: Science and Technology, Arthritis, Consumers, Drugs and Medicines, Social Sciences
-
Spending on drugs falls for first time in 55 years
ReutersThe amount of money Americans spend on prescription drugs fell for the first time in 55 years, according to a report from the IMS Institute of Healthcare Informatic. The expiration of patents on widley used drugs such drugs such as Lipitor and Plaviix...Tags: Bristol Myers Squibb Company, Pfizer Inc., Patents, Copyrights and Trademarks, Health Insurance Cost, Patient Protection and Affordable Care Act
May 21, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 16, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 14, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 8, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 9, 2013
|Story| Reuters
Original site for AstraZeneca Plc topic gallery.
